Tol2pA2-drl:APEX2-mCherry
(Plasmid
#188945)
-
PurposePlasmid for Tol2 transgenesis expressing APEX2 tagged to mitochondria and nuclei, and cytoplasmic mCherry, driven by the draculin promoter
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 188945 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbone394.pDestTol2pA2
-
Backbone manufacturerTol2Kit
- Backbone size w/o insert (bp) 5883
- Total vector size (bp) 13750
-
Vector typeTol2 destination vector (attR4-R3)
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert namedrl:mito-APEX2_p2A_APEX2-H2B_p2A_mCherry_polyA
-
SpeciesSynthetic
-
Insert Size (bp)9571
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer M13R
- 3′ sequencing primer T3 (Common Sequencing Primers)
Resource Information
-
A portion of this plasmid was derived from a plasmid made byTol2pA2 backbone from Tol2Kit (Kristen Kwan), draculin (drl) promoter from Christian Mosimann (pCM293)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Please visit https://www.biorxiv.org/content/10.1101/2020.11.12.380790v1 for bioRxiv preprint.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
Tol2pA2-drl:APEX2-mCherry was a gift from Owen Tamplin (Addgene plasmid # 188945 ; http://n2t.net/addgene:188945 ; RRID:Addgene_188945) -
For your References section:
Defining the ultrastructure of the hematopoietic stem cell niche by correlative light and electron microscopy. Agarwala S, Kim KY, Phan S, Ju S, Kong YE, Castillon GA, Bushong EA, Ellisman MH, Tamplin OJ. Elife. 2022 Aug 9;11. pii: 64835. doi: 10.7554/eLife.64835. 10.7554/eLife.64835 PubMed 35943143